Lung Transplant Infection
13
1
3
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
7.7%
1 terminated out of 13 trials
80.0%
-6.5% vs benchmark
8%
1 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (13)
AlloSure Lung Assessment and Metagenomics Outcomes Study
Liquid biopsiEs fOr luNg AllogRaft Damage classificatiOn - LEONARDO
Antimicrobial Therapeutic Drug Monitoring During Lung Transplant Perioperative Phase
Lung Transplant HCV, Pilot Study
Extracorporeal Photopheresis (ECP) After Lung Transplantation
Molecular vs Conventional Microbiologic Diagnosis for Infections in Lung Transplantation
Evaluation of Tolsura When Used as Prophylaxis After Lung Transplantation
Inhaled Beclomethasone After Community-Acquired Respiratory Viral Infection in Lung Transplant Recipients
The Effect of Early Treatment of PC945 on Aspergillus Fumigatus Lung Infection in Lung Transplant Patients.
Preliminary Study of Dornase Alfa to Treat Chest Infections Post Lung Transplant.
Transplantation Using Hepatitis C Positive Donors, A Safety Trial
Clinical Significance of Community-acquired Respiratory Virus Infection and Longitudinal Analysis of the Lung Microbiome in Lung Transplantation
Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients